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Abstract
Background: Although Candida albicans is the most common cause of fungal blood stream infections (BSIs),
infections due to Candida species other than C. albicans are rising. Candida parapsilosis complex has emerged as an
important fungal pathogen and became one of the main causes of fungemia in specific geographical areas. We
analyzed the factors related to outcome of candidemia due to C. parapsilosis in a single tertiary referral hospital
over a five-year period.
Methods: A retrospective observational study of all cases of candidemia was carried out at a 980-bedded University
Hospital in Italy. Data regarding demographic characteristics and clinical risk factors were collected from the
patient’s medical records. Antifungal susceptibility testing was performed and MIC results were interpreted
according to CLSI species-specific clinical breakpoints.
Results: Of 270 patients diagnosed with Candida BSIs during the study period, 63 (23 %) were infected with
isolates of C. parapsilosis complex which represented the second most frequently isolated yeast after C. albicans.
The overall incidence rate was 0.4 episodes/1000 hospital admissions. All the strains were in vitro susceptible to all
antifungal agents. The overall crude mortality at 30 days was 27 % (17/63), which was significantly lower than that
reported for C. albicans BSIs (42 % [61/146], p = 0.042). Being hospitalized in ICU resulted independently associated
with a significant higher risk of mortality (HR 4.625 [CI95% 1.015–21.080], p = 0.048). Conversely, early CVC removal
was confirmed to be significantly associated with a lower risk of mortality (HR 0.299 [CI95% 0.102–0.874], p = 0.027).
Finally, the type of primary antifungal therapy did not influence the outcome of infection.
Conclusions: Candidemia due to C. parapsilosis complex, the second most commonly causative agent of yeast BSIs
in our center, is characterized by a non-negligible mortality at 30 days. An early CVC removal is associated with a
significant reduced mortality.
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Background
Candida is an important cause of bloodstream infec-
tions (BSIs) and it is the main agent of invasive fungal
infection in hospitalized patients [1, 2]. Although Can-
dida albicans is the most common cause of invasive
candidiasis, infections due to Candida species other
than C. albicans are rising [3, 4]. In particular, Candida
parapsilosis complex, which includes C. parapsilosis
sensu strictu (the most frequent), Candida orthopsilosis
and Candida metapsilosis, has emerged as an important
fungal pathogen and became one of the main causes of
fungemia in tertiary-care hospitals [5–9]. Although the
mortality rate due to this species is generally lower than
that reported for other Candida species, C. parapsilosis
complex possesses several distinct features, such as its
ability to develop biofilms on intravascular devices, high
affinity for parenteral nutrition, and an intrinsic low sus-
ceptibility to echinocandins [10–12].* Correspondence: f.barchiesi@univpm.it
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Table 1 Comparison of epidemiological, clinical characteristics and outcome of patients with BSIs due to Candida parapsilosis and
Candida albicans
Variables Patients with BSIs due to:
C. parapsilosis (n = 63) C. albicans (n = 146) P valuea
Age (years), median (IQR)b 67 (43–76) 51 (66–77) 0.133
Neonates (<3 months) 1 (2) 5 (3) 0.465
Elderly (>65 years) 32 (51) 72 (49) 0.844
Male sex, n (%) 35 (56) 91 (63) 0.358
Ward
Internal Medicine, n (%) 25 (40) 52 (36) 0.448
Surgery, n (%) 17 (27) 32 (22)
Intensive Care Unit, n (%) 21 (33) 62 (43)
Comorbidities, n (%) 57 (90) 137 (94) 0.387
Chronic pulmonary diseases, n (%)c 9 (14) 11 (8) 0.127
Haematological malignancy, n (%) 1 (2) 8 (5) 0.203
Cardiovascular diseases, n (%)d 27 (43) 67 (46) 0.685
Neurological diseases, n (%)e 10 (16) 24 (16) 0.919
Gastrointestinal diseases, n (%)f 21 (33) 43 (29) 0.576
Diabetes mellitus, n (%) 8 (13) 28 (19) 0.254
Solid tumors, n (%) 15 (24) 43 (30) 0.403
Chronic renal failure, n (%) 7 (11) 12 (8) 0.504
Previous surgery (<30 days), n (%) 32 (51) 67 (46) 0.514
Gastrointestinal surgery, n (%) 8 (13) 19 (13) 0.950
Cardiovascular surgery, n (%) 13 (21) 28 (19) 0.807
Other surgery, n (%) g 12 (19) 24 (16) 0.646
Central venous catheter, n (%) 56 (89) 127 (87) 0.702
BSI CVC-related, n (%) 36 (64) 57 (45) 0.015
Other devices, n (%)h 57 (90) 129 (88) 0.653
Previous invasive procedures (<72 h), n (%)i 16 (25) 44 (30) 0.486
Parenteral nutrition, n (%) 43 (68) 105 (72) 0.592
Immunosuppressive therapy, n (%)j 18 (29) 56 (34) 0.174
Neutropenia, n (%) 4 (6) 7 (5) 0.644
Septic shock, n (%) 2 (3) 12 (8) 0.180
Prior antibiotic therapy, n (%) 58 (92) 139 (95) 0.370
Previous antifungal therapy (<30 days), n (%) 5 (8) 21 (14) 0.195
Concomitant bacteriemia, n (%) 15 (24) 40 (27) 0.588
Other coinfections, n (%)k 39 (62) 89 (61) 0.897
Appropriate antifungal therapy, n (%)l 38 (60) 92 (63) 0.712
Primary azole therapy 41 (65) 77 (53) 0.098
Primary echinocandin therapy 7 (11) 34 (23) 0.041
Primary polyene therapy 1 (2) 3 (2) 0.820
None 14 (22) 32 (22) 0.961
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The aim of this study was to analyze the factors related
to outcome of candidemia due to C. parapsilsosis com-
plex in a single institution over a five-year period.
Methods
Study population and data collection
A retrospective observational study of all cases of candide-
mia was carried out from January 1, 2010 to December 31,
2014 (5-year period) in a single 980-bedded referral Uni-
versity Hospital in Ancona, Italy. A case of Candida BSI
was defined as a peripheral isolation of Candida species
from blood culture in a patient with temporally related
clinical signs and symptoms of infection. All Candida BSIs
were identified through the microbiological laboratory
database. Data regarding demographic characteristics and
clinical risk factors were collected from the patient’s med-
ical records. Appropriate antifungal therapy was consid-
ered when an appropriate drug (based on subsequent in
vitro susceptibility testing results) with adequate dosage
was started within 72 h from the first blood culture per-
formed. Adequate dosage of an antifungal agent was de-
fined according to IDSA 2009 guidelines [13]. Early
central venous catheter (CVC) removal was defined a re-
moval of the line within 48 h from drawing blood culture.
Mortality was calculated after 7 and 30 days from the oc-
currence of the episode of Candida BSI.
Candida species were isolated from blood samples
using BacT/ALERT (bioMérieux) and identified with
standard techniques. Each of the three species of C.
parapsilosis sensu lato was identified using the MALDI-
TOF Biotyper™ [14]. Antifungal susceptibility testing was
performed using the SensitreYeastOne colorimetric plate
(SYO) (Trek Diagnostic System) and MIC results were
interpreted according to latest species-specific CBPs as
established by the CLSI [15].
The present research has been performed in accord-
ance with the ethical standards of the 1964 Declaration
of Helsinki and its later amendements. The Institutional
Review Board of the Azienda Ospedaliero-Universitaria
Ospeadali Riuniti Umberto I°-Lancisi-Salesi granted
retrospective access to the data without need for individ-
ual informed consent.
Statistical analysis
Quantitative data were shown as the median with inter-
quartile ranges (Q1–Q3). Qualitative variables were
expressed as absolute and relative frequencies. Categorical
variables were compared using the χ2 test, whereas
Mann–Whitney U test or Fisher exact test were applied
for continuous variables. Variables with a p ≤0.05 at the
descriptive analysis were analyzed by Cox regression. All
statistical analyses were performed using the statistical
package SPSS for Windows v. 20 (SPSS Inc., Chicago, IL,
USA). A P value of ≤0.05 was considered to represent stat-
istical significance and all statistical tests were two-tailed.
Results
Of 270 patients diagnosed with Candida BSIs during the
study period, 63 (23 %) were infected with isolates of C.
parapsilosis complex (95 C. parapsilosis sensu lato, 3 C.
orthopsilsosis and 2 % C. metapsilosis). This species rep-
resented the second most frequently isolated yeast after
C. albicans (146 [54 %]). The remaining infections were
due to C. tropicalis (23 [9]), C. glabrata (10 [4]) and
other Candida species (10 [4 %]). Although C. albicans
represented the most commonly isolated species, its
percentage significantly decreased from 68 % to 48 % in
the time period considered (p = 0.040). On the opposite,
there was a significant increase of the percentage of C.
parapsilosis isolation from 8 % (2010) to 30 % (2014)
(p = 0.036). The overall incidence rate of BSIs due to
C. parapsilosis was 0.4 episodes/1000 hospital
admissions.
Demographics and clinical characteristics of 63
patients infected with isolates of C. parapsilosis complex
were compared with those of 146 patients infected with
Table 1 Comparison of epidemiological, clinical characteristics and outcome of patients with BSIs due to Candida parapsilosis and
Candida albicans (Continued)
Overall mortality, n (%) 17 (27) 61 (42) 0.042
Early mortality (days 1–7), n (%) 4 (6) 24 (17) 0.049
Late mortality (days 8–30), n (%) 13 (21) 37 (25) 0.464
aComparisons between groups were performed using Wilcoxon rank sum test for quantitative variables and Chi-Square test (or Fisher Exact Test when expected
frequencies were less than five) for qualitative variables
bIQR, Interquartile range
cChronic pulmonary diseases include asthma, chronic bronchitis, emphysema and lung fibrosis
dCardiovascular diseases include heart failure, ischemic heart disease, endocarditis and arrhythmia
eNeurological diseases include Parkinson’s disease, Alzheimer’s disease and paralysis
fGastrointestinal diseases include Crohn’s disease, ulcerative colitis, chronic pancreatitis and gallbladder stones
g Other surgery includes plastic surgery, thoracic surgery, orthopaedic surgery, urological surgery and neurosurgery
h Other devices include urinary catheter, surgical drainage, cutaneous gastrostomy and tracheostomy tube
iPrevious invasive procedures include endoscopy and positioning of any device
jImmunosuppressive therapy include corticosteroids, calcineurin inhibitors and monoclonal antibodies
kOther coinfections include bacterial and/or fungal infections in sites other than blood
lAppropriate antifungal therapy was considered when the appropriate drug with adequate dosage was started ≤ 72 h from the first blood culture performed
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Table 2 Outcome of 63 patients with BSIs due to Candida parapsilosis complex considered in this study
Characteristics 30-day outcome
Survival (n = 46) Death (n = 17) P valuea
Age (years), median (IQR)b 62 (31–75) 76 (63–78) 0.046
Male sex, n (%) 24 (52) 11 (65) 0.374
Ward
Internal Medicine, n (%) 21 (46) 4 (24) 0.033
Surgery, n (%) 14 (30) 3 (18)
Intensive Care Unit, n (%) 11 (24) 10 (59)
Comorbidities, n (%) 40(87) 17(100) 0.117
Chronic pulmonary diseases, n (%)c 5(11) 4 (24) 0.235
Haematological malignancy, n (%) 1 (2) 0 (0) 0.540
Cardiovascular diseases, n (%)d 15 (33) 12(71) 0.006
Neurological diseases, n (%)e 9 (20) 1(6) 0.263
Gastrointestinal diseases, n (%)f 16 (35) 5 (29) 0.688
Diabetes mellitus, n (%) 4 (9) 4 (24) 0.195
Solid tumors, n (%) 9 (20) 6 (35) 0.193
Chronic renal failure, n (%) 5 (11) 2 (12) 1.000
Previous surgery (<30 days), n (%) 23(50) 9(53) 0.835
Gastrointestinal surgery, n (%) 5(11) 3(18) 0.671
Cardiovascular surgery, n (%) 7(15) 6(35) 0.080
Other surgery, n (%)g 11(24) 1 (6) 0.154
Central venous catheter, n (%) 41(89) 15 (88) 0.920
BSI CVC-related, n (%) 25 (61) 11 (73) 0.460
Early central venous catheter removal, n (%)h 41 (100) 11 (73) <0.0001
Other devices, n (%)i 40 (87) 17(100) 0.178
Previous invasive procedures (<72 h), n (%)j 9 (20) 7 (41) 0.080
Parenteral nutrition, n (%) 29 (63) 14 (82) 0.143
Immunosuppressive therapy, n (%)k 13(28) 5(29) 0.920
Neutropenia, n (%) 3 (7) 1 (6) 1.000
Septic shock, n (%) 1(2) 1(6) 0.470
Prior antibiotic therapy, n (%) 42 (91) 16 (94) 0.713
Previous antifungal therapy, n (%) 4 (9) 1 (6) 0.713
Concomitant bacteriemia, n (%) 12(26) 3(18) 0.487
Other coinfections, n (%)l 28 (61) 11(65) 0.780
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isolates of C. albicans and the results are shown in
Table 1. Median patients age was 67 years. Male
accounted for 56 % of the population. Twenty-five iso-
lates were recovered from patients hospitalized in med-
ical wards, 21 from patients hospitalized in ICUs and 17
from patients hospitalized in surgical wards. The major-
ity of patients (90 %) suffered from multiple comorbidi-
ties (range 2 to 4) being the most common
cardiovascular (43) and gastrointestinal (33 %) diseases.
A total of 51 % of patients underwent a surgical inter-
vention within 30 days from the onset of candidemia. In
comparison with C. albicans, BSIs due to C. parapsilosis
were significantly more often associated with the use of
CVC (p = 0.015). The overall crude mortality at 30 days
was higher in patients infected with C. albicans than C.
parapsilosis (42 % vs 27 %, respectively, p = 0.042).
Factors related to outcome of 63 patients with BSIs
due to C. parapsilosis are reported in Table 2. Older age
(p = 0.046), being hospitalized in ICU or in medical
wards rather than in surgical wards (p = 0.033), being
recently diagnosed with a cardiovascular disease (p =
0.006), and the lack of an early CVC removal (p = 0.003)
were all factors associated with a significant higher prob-
ability of death at the descriptive analysis. On multivari-
ate analysis, being hospitalized in ICU resulted
independently associated with a significant higher risk of
mortality (HR 4.625 [CI95% 1.015–21.080], p = 0.048).
Conversely, early CVC removal was confirmed to be sig-
nificantly associated with a lower risk of mortality (HR
0.299 [CI95% 0.102–0.874], p = 0.027).
Table 3 shows the results of antifungal susceptibility
testing to nine antifungal agents as routinely performed
by the SYO method which was developed to provide an
easy alternative to the CLSI procedure. With the excep-
tion of one isolate that showed to be susceptible dose
dependent to fluconazole (MIC 4 μg/ml) and two iso-
lates which were found to have non-wild type phenotype
for flucytosine (MIC 1 μg/ml), all isolates showed to be
fully susceptible to all antifungals according to the CLSI
interpretation [15].
Table 2 Outcome of 63 patients with BSIs due to Candida parapsilosis complex considered in this study (Continued)
Appropriate antifungal therapym 30 (65) 8 (47) 0.190
Primary azole therapy 32 (70) 9 (53) 0.219
Primary echinocandin therapy 5 (11) 2 (12) 1.000
Primary polyene therapy 1 (2) 0 (0) 1.000
None 8 (17) 6 (35) 0.129
aComparisons between groups were performed using Wilcoxon rank sum test for quantitative variables and Chi-Square test (or Fisher Exact Test when expected
frequencies were less than five) for qualitative variables
b IQR, Interquartile range
cChronic pulmonary diseases include asthma, chronic bronchitis, emphysema and lung fibrosis
dCardiovascular diseases include heart failure, ischemic heart disease, endocarditis and arrhythmia
eNeurological diseases include Parkinson’s disease, Alzheimer’s disease and paralysis
fGastrointestinal diseases include Crohn’s disease, ulcerative colitis, chronic pancreatitis and gallbladder stones
gOther surgery includes plastic surgery, thoracic surgery, orthopaedic surgery, urological surgery and neurosurgery
h Early CVC removal was considered occurring within 48 h from blood cultures drawing
i Other devices include urinary catheter, surgical drainage, cutaneous gastrostomy and tracheostomy tube
j Previous invasive procedures include endoscopy and positioning of any device
kImmunosuppressive therapy include corticosteroids, calcineurin inhibitors and monoclonal antibodies
l Other coinfections include bacterial and/or fungal infections in sites other than blood
mAppropriate antifungal therapy was considered when the appropriate drug with adequate dosage was started within 72 h the first blood culture performed
Table 3 In vitro susceptibilities of Candida parapsilosis complex isolates considered in this study
Antifungal agents MIC range (μg/ml) MIC50 (μg/ml) MIC90 (μg/ml) % of isolates in the indicated category according to CLSIa
S SDD I R WT Non-WT
Amphotericin B ≤0.12–1 0.5 0.5 - - - - 100 0
Flucytosine ≤0.06–1 ≤0.06 0.25 - - - - 97 3
Fluconazole ≤0.12–4 0.25 1 98.4 1.6 - 0 - -
Itraconazole ≤0.015–0.25 0.06 0.12 - - - - 100 0
Voriconazole ≤0.008–0.06 ≤0.008 0.015 100 0 - 0 - -
Posaconazole ≤0.008–0.12 0.03 0.06 - - - - 100 -
Caspofungin 0.06–1 0.25 0.5 100 - 0 0 - -
Anidulafungin 0.12–2 0.5 2 100 - 0 0 - -
Micafungin 0.12–2 1 2 100 - 0 0 - -
aCategory was interpreted according to CLSI breakpoints as reported in ref. 15. S, susceptible; SDD susceptible dose dependent, I intermediate, R resistant, WT
wild type
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Discussion and conclusions
Although C. albicans remains the most common fungal
isolate from blood, longitudinal studies showed a trend
toward an increased prevalence of other Candida spp.
with a larger proportion of C. glabrata in the United
States and C. parapsilosis in some European (i.e.: Italy or
Spain) and Latin American countries [3–9]. As far, few
studies focused on the specific predictors influencing the
outcome of BSIs due to C. parapsilosis [16–18].
First, we confirmed that the mortality due to this
species is somewhat lower than that reported for C. albi-
cans, having found a rate of 27 % at 30 days. This figure
is consistent with literature data in which the 30-day
mortality due to this species ranges from 23 % to 30 %
[14, 19–21].
Second, hospitalization in ICU showed to be inde-
pendently associated with higher risk of mortality. Our
data are in agreement with a large study showing a mor-
tality rate increasing from 29 % to 47 % in patients with
BSIs due to Candida spp. hospitalized, respectively, in
non-ICU and ICU wards [22]. ICU stay would represent
a surrogate marker of illness severity thereby facilitating
the poor outcome of this population group.
Third, we showed that early CVC removal is protective
in BSIs due to C. parapsilosis. Although the impact of
CVC management has been extensively investigated on
the outcome of patients with candidemia, few studies
have examined this issue across individual Candida spe-
cies. Two recent studies showed that CVC removal
exerted a protective effect on the outcome of candide-
mia due to C. parapsilosis [14, 20]. Since this species is
characterized by a high propensity to develop biofilms
on intravascular devices, their early removal play a fun-
damental role in determining the outcome of infection.
Fourth, we found that the outcome was not influenced
by an appropriate antifungal therapy. Despite this finding
is somewhat divergent from that reported by the current
literature [23–25], there is a paucity of data considering
the infection outcome of individual Candida species. In
this regard, there are two important factors to consider.
First, being C. parapsilosis less pathogenic than other
Candida species (i.e.: C. albicans and C. tropicalis) [17],
BSIs due to this entity could be more deeply affected by a
correct general management (i.e.: prompt removal of any
central line) rather than an early therapeutic intervention.
Second, we defined appropriate antifungal therapy as the
appropriate drug with adequate dosage started within 72 h
from the first blood culture performed. Since C. parapsilo-
sis has a time to positivity of blood cultures longer than
those reported for C. albicans and C. tropicalis [26], pre-
liminary blood culture showing the growth of yeast-like
fungal pathogen could be delayed thereby determining an
initial, although adequate, antifungal treatment after this
time interval.
Interestingly, we found that primary antifungal treat-
ment (i.e.: triazoles or echinocandins) did not influence
the outcome of C. parapsilosis BSIs. Although, this Can-
dida species possesses a natural low susceptibility profile
to echinocandins [12] and there is still a debate on the use
of these molecules in infections caused by this species, ei-
ther randomized or not-randomized clinical trials have
shown not significant differences in the success rates
between arms [27–30]. Our data, although with a limited
number of patients, corroborated these findings.
The present study have some limitations. First, being a
single-center study, the number of patients considered is
low. This feature has certainly weakened the statistical
power of the study. Nevertheless, we have made all at-
tempts to collect and analyze as many as clinical data as
possible to reveal useful information for the manage-
ment of patients infected with this Candida species. Sec-
ond, being a retrospective study encompassing several
departments and medical disciplines over a five years
period, there was not a univocal management of each in-
dividual case. In this respect, serial follow-up blood cul-
tures were not systematically performed and we were
unable to include important parameters, other then 30-
day mortality, such as the persistence of positive blood
cultures after the initiation of antifungal therapy.
In conclusion, our study shows that candidemia due to
C. parapsilosis complex, the second most commonly
causative agent of yeast BSIs in our center, is character-
ized by a non-negligible mortality at 30 days. While an
early CVC removal is associated with significant reduced
mortality, the type of primary antifungal therapy does
not influence the outcome. Further prospective studies
including higher number of patients are needed to cor-
roborate these findings.
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